How Sodium Polystyrene Sulfonate Works
Sodium polystyrene sulfonate (SPS/Kayexalate) is a cation-exchange resin that binds potassium in the gastrointestinal tract in exchange for sodium, increasing fecal potassium excretion and lowering serum potassium levels. 1
Mechanism of Action
SPS functions as a non-absorbed polymer that operates primarily in the distal colon 2. The drug contains sodium counterions that are released as the resin passes through the intestinal tract. As these sodium ions are freed, they are replaced by potassium ions from the gastrointestinal lumen 1. This binding reduces free potassium concentration in the gut, which subsequently draws potassium from the bloodstream into the intestinal lumen, ultimately lowering serum potassium levels 2.
Key Pharmacologic Characteristics:
- Exchange ratio: The practical exchange ratio is 1 mEq of potassium per 1 gram of resin 1
- Site of action: Primarily the large intestine/colon, which excretes potassium to a greater degree than the small intestine 1
- Sodium content: Each gram of SPS contains 4.1 mEq (100 mg) of sodium 1
- In vivo efficiency: Only approximately 33% efficient at sodium-potassium exchange 1
Pharmacodynamics and Onset
The onset of action is variable and unpredictable, ranging from several hours to days 2. This delayed and inconsistent response is a critical limitation of SPS. The efficiency of the potassium-binding process is inherently limited and varies considerably between patients 1.
Non-Selectivity Issues
SPS is nonselective for potassium and also binds other cations including calcium and magnesium 2. This lack of selectivity can lead to:
- Hypocalcemia
- Hypomagnesemia
- Hypokalemia (with excessive dosing)
- Systemic alkalosis 2
Additionally, SPS can bind to other oral medications, potentially reducing their absorption and efficacy 1. For this reason, other oral medications should be separated from SPS by at least 3 hours (or 6 hours in patients with gastroparesis) 1.
Critical Safety Concerns
The chronic use of SPS should be avoided due to severe gastrointestinal toxicity risks 3. Multiple guidelines and regulatory agencies have raised concerns about:
- Intestinal ischemia and colonic necrosis (including fatal cases) 2
- Doubling of risk for serious gastrointestinal adverse events requiring hospitalization 2
- Overall mortality rate of 33% in patients experiencing gastrointestinal complications 2
- Transmural necrosis as the most common histopathologic finding (62% of adverse event cases) 4
Importantly, these severe adverse events occur both with and without sorbitol co-administration 4, contradicting the previous belief that sorbitol was the primary culprit. The colon is the most common site of injury (76% of cases) 4.
Evidence Quality Limitations
SPS has never undergone rigorous placebo-controlled clinical trials to prove its efficacy and safety for acute or chronic hyperkalemia 3. Only one small randomized, double-blind 7-day trial exists, which showed a mean potassium decrease of 1.04 mEq/L compared to placebo 2. This paucity of high-quality evidence stands in stark contrast to newer potassium binders (patiromer and sodium zirconium cyclosilicate), which have robust phase 2 and 3 trial data 2.
Clinical Implications
Given the unpredictable efficacy, delayed onset, significant sodium load (1500 mg per 15 g dose), and serious safety concerns, current guidelines recommend considering newer potassium binders as alternatives 3. The newer agents (patiromer and SZC) have faster, more predictable onset times (7 hours and 1 hour respectively) and have not been associated with serious gastrointestinal adverse events in randomized trials 2.
For patients who cannot tolerate sodium load (heart failure, severe hypertension, marked edema), SPS is particularly problematic due to its high sodium content 3. In these cases, potassium binders with different counter-exchange ions should be strongly preferred 3.